A Randomized Double-Blind Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects with Moderate-to-Severe Atopic Dermatitis Treated with Nemolizumab

Adult subjects over the age of 18 through age 54 diagnosed with Atopic Dematitis. The research study is being conducted to learn how an investigational drug called nemolizumab affects the immune response to vaccines. Procedures include Physical exam, Medical History, Vital signs, Blood and Urine tests, Electrocardiogram and Subject Questionnaires Key eligibility include Chronic AD for at least 2 years before the screening visit, EASI score greater than 16 and IGA score greater than 3 at both the screening and baseline visits, AD involvement greater than 10% of BSA at both the screening and baseline visits

You may be eligible for this study if you meet the following criteria:

• Conditions: Atopic Dermatitis
• Age: 99 years or below
• Gender: All